# Identification of Inhibitors of the Disease-Associated Protein Phosphatase Scp1 Using Antibody Mimetic Molecules

## TL;DR

Researchers developed a specific inhibitor for the disease-related protein Scp1 using antibody-like molecules, which could help in treating diseases like cancer.

## Contribution

The study introduces FG-1Adn, a novel adnectin molecule that specifically inhibits Scp1 with high affinity and functional impact.

## Key findings

- FG-1Adn binds Scp1 with high specificity and affinity, targeting its substrate-recognition site.
- Hydrophobic and aromatic amino acids are crucial for Scp1 recognition by FG-1Adn.
- FG-1Adn inhibits Scp1 function in cells, increasing phosphorylation of its target protein.

## Abstract

Protein phosphorylation is a prevalent translational modification, and its dysregulation has been implicated in various diseases, including cancer. Despite its significance, there is a lack of specific inhibitors of the FCP/SCP-type Ser/Thr protein phosphatase Scp1, characterized by high specificity and affinity. In this study, we focused on adnectin, an antibody-mimetic protein, aiming to identify Scp1-specific binding molecules with a broad binding surface that target the substrate-recognition site of Scp1. Biopanning of Scp1 was performed using an adnectin-presenting phage library with a randomized FG loop. We succeeded in identifying FG-1Adn, which showed high affinity and specificity for Scp1. Ala scanning analysis of the Scp1-binding sequence in relation to the FG-1 peptide revealed that hydrophobic residues, including aromatic amino acids, play important roles in Scp1 recognition. Furthermore, FG-1Adn was found to co-localize with Scp1 in cells, especially on the plasma membrane. In addition, Western blotting analysis showed that FG-1Adn increased the phosphorylation level of the target protein of Scp1 in cells, indicating that FG-1Adn can inhibit the function of Scp1. These results suggest that FG-1Adn can be used as a specific inhibitor of Scp1.